newsfilter
← Latest News
GlobeNewswire·

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells1 provides new insights into simufilam’s